Gilead Sciences, Inc.
GILD
Positions held
Your positionsGILD isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Gilead Sciences is strategically positioned in the healthcare sector, focusing on innovative therapies that address unmet medical needs, which enhances its competitive edge.
- Revenue increased by 12% in the latest quarter, reaching $7.8 billion compared to $7.0 billion in the previous quarter.
- Gross margin improved to 79.8%, up from 79.2% in the prior quarter.
- Gilead faces challenges with a negative profit margin of -10.64%, indicating potential issues with cost management and profitability.
- Net income for the latest quarter was -$10.5 billion, highlighting significant financial strain.
- Operating margin decreased to 32.5%, down from 38.7% in the previous quarter, reflecting declining operational efficiency.
Fundamentals
| Market cap | $182.40B | Enterprise value | $203.68B | Trailing P/E | — | Forward P/E | 14.87 |
| PEG | 2.18 | Price / book | 15.43 | Beta | 0.33 | Dividend yield | 2.23% |
| Revenue growth | 10.2% | Earnings growth | — | Gross margin | 79.6% | Operating margin | 33.7% |
| Profit margin | -10.6% | ROE | -20.7% | ROA | 14.1% | Debt / equity | 2.23 |
| Current ratio | 1.27 | Free cash flow | $9.77B | Analyst recommendation | buy | Mean target | $159.38 |
| 52w high | $157.29 | 52w low | $114.02 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $7.8B | $7.0B | $7.9B | $7.8B | $7.1B | — |
| Op margin | 32.5% | 38.7% | 37.7% | 45.0% | 38.5% | — |
| Net income | -$10.5B | $2.0B | $2.2B | $3.1B | $2.0B | — |
| Gross margin | 79.8% | 79.2% | 79.5% | 79.8% | 78.8% | — |
| Gross profit | $6.2B | $5.5B | $6.3B | $6.2B | $5.6B | — |
| Operating income | $2.5B | $2.7B | $3.0B | $3.5B | $2.7B | — |
- Revenue +12% vs prior quarter ($7.8B vs $7.0B).
- Gross margin 79.8% (was 79.2% prior quarter).
- Operating margin compressed to 32.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $29.4B | $28.8B | $27.1B | $27.3B |
| Op margin | 39.7% | 36.9% | 32.6% | 40.2% |
| Net income | $8.5B | $480M | $5.7B | $4.6B |
| Gross margin | 78.8% | 78.3% | 76.0% | 79.3% |
| Gross profit | $23.2B | $22.5B | $20.6B | $21.6B |
| Operating income | $11.7B | $10.6B | $8.8B | $11.0B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
2026-10-08 · What Is Cognizant Technology Solutions (CTSH) Signaling With Its Latest AI Push?
2026-10-08 · RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating
2026-10-07 · Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?
2026-10-07 · Is Exelixis Stock Engineered To Make You Money?
2026-10-07 · Is Abbott Laboratories (ABT) a Dividend Bargain After Its 2026 Selloff?
2026-10-07 · Morgan Stanley Adjusts Price Target on Gilead Sciences to $163 From $165
2026-10-07 · JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160
2026-10-07 · Gilead Sciences signs five-year DevOps agreement with Cognizant
2026-10-07 · Gilead Sciences signs five-year DevOps agreement with Cognizant
2026-10-06 · Cognizant, Gilead Sign 5-Year Tech Extension Covering DevOps, AI Tools
2026-10-06 · Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Price (daily)
Full chart · RSI · MACD · patterns